Molavir (Molnupiravir) 200mg

Inquire / Price
  • Model Number:
  • Brand Name:
  • Origin:
    Generic drug, LAOS.
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

  • Details
  • Description
  • Packaging Size
  • Strength
  • Compositon
  • Treatment
    Treatment COVID-19 in Adult testing positive and (SARS-CoV-2) virus
  • Form
  • Brand
  • Quantity Unit
  • Manufacturer
    Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.(TLPH)

Molavir (Molnupiravir)200mg

Dosage Forms : Capsule

Strengths: 200mg

COVID-19 Disease Treatment

Treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and who are at high risk for progression to severe COVID-19, including hospitalization or death

800 mg PO q12hr for 5 days.

Initiate as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset

Completing the full 5-day treatment course and continuing to isolate in accordance with public health recommendations are important to maximize viral clearance and minimize viral transmission

If patient is hospitalized due to severe or critical COVID-19 after starting treatment with Molnupiravir, completion of the full 5-day treatment is at the healthcare provider’s discretion

Dosage Modifications

Renal impairment

  • Mild or moderate (eGFR >30 mL/min): No dosage adjustment necessary
  • Severe (eGFR <30 mL/min), end-stage renal disease, or patients on dialysis: Pharmacokinetics not evaluated; not expected to have a significant effect on NHC (N4-hydroxycytidine) exposure

Hepatic impairment

  • Mild to severe (Child-Pugh Class A to C): No dosage adjustment required
  • Preclinical data indicate that hepatic elimination is not expected to be a major route of NHC elimination

Dosing Considerations

Verify pregnancy status in females of childbearing potential before initiating

Limitations of use

  • Not authorized for use in patients aged <18 years
  • Not authorized for initiation of treatment in patients requiring hospitalization owing to COVID-19
  • Not authorized for use for >5 consecutive days
  • Not authorized for preexposure or postexposure prophylaxis for prevention of COVID-19.

Adverse Effects


Diarrhea (2%)

Nausea (1%)

Dizziness (1%)


  • Selected Grade 3 and 4 laboratory abnormalities in chemistry (ALT, AST, creatinine, and lipase) and hematology (hemoglobin, platelets, and leukocytes)

Required reporting for serious adverse events and medication errors

Prescribers and/or the provider’s designee are/is responsible for mandatory reporting of all serious adverse events and medication errors potentially drug-related within 7 calendar days from the onset of the event

Serious adverse events are defined as

  • Death or a life-threatening adverse event;
  • A medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly;
  • Inpatient hospitalization or prolongation of existing hospitalization;
  • A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or
  • A congenital anomaly/birth defect


There are limited clinical data available; serious and unexpected adverse events may occur that have yet to be reported

May cause fetal harm when administered to pregnant females

Bone and cartilage toxicity

  • Not authorized for use in patients aged <18 years owing to possible effects on bone and cartilage growth
  • Bone and cartilage toxicity was observed in rats after repeated dosing
  • Safety and efficacy have not been established in pediatric patients

Missed dose

  • <10 hours: Take missed dose as soon as possible, and resume normal dosing schedule
  • >10 hours: Skip dose, and take the next dose at the regularly scheduled time
  • Do not double dose to make up for missed dose


Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)